New Delhi, Nov 6 (PTI) Drug firm Lupin on Thursday reported a 73 per cent year-on-year increase in its consolidated profit after tax to Rs 1,485 crore in the September quarter, led by robust sales in the US and emerging markets.

The Mumbai-based drug maker reported a profit after tax (PAT) of Rs 859 crore for the July-September quarter of the last fiscal.

Sales rose to Rs 6,831 crore for the second quarter compared with Rs 5,497 crore in the year-ago period, Lupin Ltd said in a statement.

"We continue to see robust growth in revenues and EBITDA led by strong performance across the board, in the US, emerging markets, other developed markets and in India, supported by higher operational efficiencies and sustained investments. We intend to leverage the performance of H1 to deliver a strong

See Full Page